The abstract is read at the publisher; the summary is JClub's.
Disease-free survival and distant metastasis-free survival are strong surrogate endpoints for disease-specific survival in resected melanoma, with R2 up to 0.95 at 24–36 months.
- Why it matters: Many adjuvant trials rely on recurrence-based surrogates without formal trial-level validation, and it is unclear which endpoints best support interim analyses and regulatory decisions.
- What they did: Using 10,379 stage I–III melanoma patients from 5 international centers (2000–2023), the study assessed trial-level surrogacy via center-specific log hazard ratios and restricted mean survival time at 12–48 month horizons, with OS evaluated by Kendall’s τ and truncated primary endpoints at 60 months.
- The result: DFS surrogacy for DSS was strongest at 24–36 months (R2 up to 0.95), DMFS showed consistently high DSS surrogacy from 24–48 months (R2 0.87–0.91), while OS correlations were weak at all horizons (R2<0.40) and surrogacy varied by pT stage.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.